glucose load [3, 4] . In healthy individuals, this so-called "incretin effect" accounts for 50−70% of postprandial insulin secretion [5] . The two known incretin hormones are GLP-1 (secreted predominantly from the distal small intestine and colon) and gastrointestinal insulinotropic polypeptide (GIP; secreted mainly from the proximal small intestine). The insulinotropic property of GIP was documented in 1973 [6] and that of GLP-1 in 1985 [7] . The release of incretin hormones is stimulated by the interaction of nutrients (and also bile salts in the case of GLP -1) with the intestine. Both are rapidly degraded in the circulation by a ubiquitous enzyme called DPP-4, so that the plasma half-life of the active molecules is only a few minutes [8, 9] . In 1986, Nauck and colleagues [10] reported that the magnitude of the incretin effect was diminished in patients with T2DM. While this may potentially represent an epiphenomenon of pancreatic beta-cell failure, it is clear that the secretion of both GIP and GLP-1 is relatively intact in T2DM; but while the insulinotropic property of GLP-1 is preserved, that of GIP is markedly diminished, probably partly as an effect of hyperglycemia [11] . Pharmaceutical development has thus hitherto focused primarily on agents based on the action of GLP-1, i.e., DPP-4 inhibitors and GLP-1 receptor agonists, which are resistant to degradation by DPP-4 [12] . A fundamental advantage of GLP-1-based therapy is that it targets the islet cell "defects" of insufficient insulin, and excessive glucagon, secretion in T2DM. Importantly, the insulinotropic and glucagonostatic properties of GLP-1 are glucose-dependent, with a threshold for these effects of approximately 8 mmol/L, so that there is minimal, if any, risk of hypoglycemia. These drugs also target fasting, as well as pre and postprandial glycemia; the latter is now recognized as a major determinant of "average" glycemic control, as assessed by [1] . These therapies are associated with different adverse effects; notably, the use of insulin and insulin secretagogs is associated with an increased propensity for hypoglycemia and weight gain [2] .
The recent availability of "incretin-based" therapies, comprising of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, represents a major advance given that these drugs do not increase the risk of hypoglycemia significantly. inhibitors are weight neutral, while the use of GLP-1 receptor agonists is associated with modest weight loss [1, 2] . The development of these drugs has followed the recognition that the incretin system is pivotal to the regulation of blood glucose homeostasis. It was reported in 1964 that the insulin response to an enteral, or oral, glucose load is substantially greater than that induced by an iso-glycemic intravenous and GLP-1 receptors are expressed widely throughout multiple body systems, including the pancreas, brain, heart, kidney, and gastrointestinal tract.
It has generally been assumed that GLP-1 regulates glucose homeostasis through effects on islet cell function [16] [17] [18] , which are certainly important, especially in relation to the glucose dependency of the insulinotropic and glucagonostatic properties of GLP-1 [19] , and are of particular relevance to fasting glycemia. However, because the human stomach empties at an overall rate of 1−4 kcal/min in health [20, 21] , most humans are predominantly in the postprandial or postabsorptive state, with the duration of fasting limited, in most cases, to perhaps about 4 h before breakfast. Moreover, gastric empting is often abnormally delayed (and occasionally, more rapid) in patients with T2DM and is a major determinant of postprandial glycemia [22] [23] [24] . In T2DM patients with delayed emptying, the magnitude of this delay is often modest [22] [23] [24] , hence the fact that both endogenous and exogenous GLP-1 slow gastric emptying is of fundamental significance. Moreover, the secretion of GLP-1 is dependent on the small intestinal glucose load being released in much greater amounts when the rate of carbohydrate exposure is at the upper end of the normal physiological range [25] .
Using the GLP-1 receptor antagonist, exendin , it was shown that endogenous GLP-1 is a physiologic modulator of gastric emptying [26] .
When GLP-1 was administered exogenously to healthy individuals [27, 28] and patients with T2DM [29] , there was an overall marked (but variable) slowing of gastric emptying.
The reduction in postprandial glycemia induced by acute administration of GLP-1 was shown to be related to the magnitude of the slowing of gastric emptying [28] ; glycated hemoglobin (HbA 1c ), particularly as glycemic control improves [1] . Several GLP-1 receptor agonists are available and are increasingly used both as monotherapy and as "add-on" to other agents, particularly metformin, and more recently, basal insulin [13] [14] [15] . 
METHODS

Pubmed was searched for English language
articles that evaluated the pharmacokinetics, efficacy, safety and mode of action of lixisenatide (without time limits). The search parameters were "glucagon-like peptide-1 receptor agonists," "lixisenatide," "efficacy," "safety," "mechanism of action," and "pharmacokinetics." Original research articles, reviews and other articles of interest were reviewed. References of key reviews were also reviewed to ensure that all data sources were captured. In addition, a number of abstracts and posters on lixisenatide presented at key diabetes congresses were also reviewed when available in the public domain. From these sources, the most important information was identified for inclusion in this review. Abstracts and posters citing data that are now published were excluded from this review.
The GLP-1 Receptor as a Therapeutic Target
GLP-1 receptor agonists target several metabolic abnormalities in the T2DM phenotype, the latter is greater when "baseline" gastric emptying is relatively more rapid [30] . That the reduction in postprandial glycemia induced by exogenous GLP-1 is associated with a reduction, rather than an increase, in insulin indicates that slowing of gastric emptying outweighs the insulinotropic property of GLP-1 in this situation [28, 29, 31] . Not surprisingly, administration of the gastrokinetic drug, erythromycin, suppressed the GLP-1-induced slowing of gastric emptying and attenuated its effect to reduce postprandial glycemia [32] .
Therefore, it is arguable whether or not GLP-1 should be regarded as a true incretin, at least postprandially. A recent study suggests that the slowing of gastric emptying by exogenous GLP-1 may be subject to tachyphylaxis with sustained exposure [33] . When two drinks were given to healthy individuals at an interval of 4 h, GLP-1 slowed gastric emptying of both drinks, but the magnitude of the slowing of the second drink was less. It was suggested that tachyphylaxis may occur at the level of the vagus nerve [33] . While the study had methodological limitations, the conclusions are likely to be valid and of major relevance to the effects of different GLP-1 receptor agonists.
GLP-1 is also involved in the regulation of appetite and energy intake. For example, in obese individuals there was a reduction in hunger and food consumption after infusion of GLP-1 [34] , and in patients with T2DM, a continuous, subcutaneous infusion of GLP-1 over a 6-week period reduced appetite and resulted in an average weight loss of 1.9 kg [35] . Studies in animals suggest that GLP-1 has the capacity to promote β-cell proliferation [36] , inhibit apoptosis [37] , and thereby preserve or expand β-cell mass [38] . It remains to be determined whether this is also the case in human T2DM. [55] . Scintigraphy is the "gold standard" technique to quantify gastric emptying [56, 57] , while the use of stable isotope breath tests and ultrasonography are acceptable alternatives [57] [58] [59] . However, in many studies relating to the effect of GLP-1 receptor agonists on gastric emptying, the latter has been assessed using the less-than-optimal paracetamol absorption method [42] [43] [44] 60] .
With the latter technique, it has been reported in rats that the delay of gastric emptying induced by liraglutide diminishes within 14 days, whereas the comparable initial delay induced by exenatide IR is sustained (Fig. 1) [60] .
In patients with T2DM, after 14 weeks' a d m i n i s t r a t i o n , e x e n a t i d e I R s l o w e d paracetamol absorption significantly, while exenatide long-acting release (LAR) had no significant effect [44] . Liraglutide does, however, have a modest effect to delay paracetamol absorption after administration for 3 weeks in patients with T2DM, which correlates with the reduction in postprandial glucose [42] . In contrast, exenatide IR has been shown to slow gastric emptying markedly in T2DM after administration for 5 days, as assessed by scintigraphy [55] . These observations are presumably attributable to the "tachyphylaxis" phenomenon reported by Nauck et al. [33] . proline deletion [61] . Lixisenatide is unique in that it is "short-acting," but administered as a once-daily dose; this is believed to be partly due to its marked ability to delay gastric emptying (Table 1) secretion may be impaired [62] [63] [64] .
RESULTS
Pharmacokinetic and Dosing Studies
Lixisenatide exhibits dose-dependent pharmacokinetics. In a 4-week, randomized, placebo-controlled, dose-ranging study in efficacy to tolerability ratio [65] .
Mechanisms of Efficacy
The mechanisms by which lixisenatide exerts its glucose-lowering effect have been investigated in several studies, which have demonstrated effects of lixisenatide on multiple factors involved in glucose regulation [66] [67] [68] . Glucose disposition was also accelerated 2.3-fold, and a reduction in blood glucose below counterregulatory thresholds (<3.9 mmol/L) was evident in some subjects [66] . 
Effect of Lixisenatide as Monotherapy and as "Add-On" to Oral Antidiabetic Agents
The effect of lixisenatide on glycemia both as monotherapy and as "add-on" to oral antidiabetic agents (OADs) has been evaluated 
Postprandial Glucose
A s m o n o t h e r a p y i n G e t G o a l -M O N O ,
lixisenatide had a pronounced effect on PPG associated with breakfast, with improvements in 2-h postprandial glucose levels (P < 0.001 vs.
placebo) and a 75% reduction versus placebo in the postprandial glucose excursion, as measured during a standardized breakfast (Fig. 3 ) [77] . Fig. 3 Changes in 2-h postprandial glucose and 2-h glucose excursion a er 12 weeks of treatment with lixisenatide 20 µg two-step (10 µg for 1 week, 15 µg for 1 week, and then 20 µg; n = 120), lixisenatide one-step (10 µg for 2 weeks and then 20 µg; n = 119), placebo two-step (n = 61), or placebo one-step (n = 61) (placebo groups were combined for analyses). Data are from patients with T2DM not receiving glucose-lowering therapy undergoing a standardized breakfast meal. Glucose excursion = 2-h PPG, plasma glucose 30 min before the meal test before study drug administration. Lixisenatide one-step and two-step titration reduced both 2-h PPG and 2-h glucose excursions versus placebo. Data shown are mean ± SD. Reproduced with permission from Fonseca VA, et al. Diabetes Care. 2012;35:1225-31 [77] . PPG postprandial glucose, T2DM type 2 diabetes mellitus lixisenatide in patients suboptimally controlled on metformin in the GetGoal-M study [72] and sulfonylureas in the GetGoal-S study [73] .
2-h PPG 2-h glucose excursion
Glycated Hemoglobin
As monotherapy in a 12-week trial (GetGoal- Lixisenatide has also been shown to reduce
HbA 1c levels in patients suboptimally controlled on either a sulfonylurea in the GetGoal-S trial [73] or a thiazolidinedione in the GetGoal-P trial [74] .
In both of these 24-week trials, lixisenatide increased the proportion of patients achieving HbA 1c <7%
(GetGoal-S 36.4% vs. 13.5%; GetGoal-P 52% vs.
26%, for lixisenatide and placebo, respectively; P < 0.0001) [73, 74] .
Body Weight
In the studies of lixisenatide in combination with OADs, patients had a mean baseline body mass index (BMI) of ≥30 kg/m 2 ( Table 2) and were offered diet and lifestyle counseling consistent with international or local guidelines for patients with T2DM, in addition to study smaller reductions in body weight were evident in other studies [72, 74] . In GetGoal-X, mean baseline body weight was slightly higher in the exenatide group (96.1 vs. 94.0 kg for lixisenatide), but mean BMI was similar (Table 2) . In this study, body weight decreased from baseline in both groups: −2.96 kg with lixisenatide once daily and −3.98 kg with exenatide twice daily (LS mean difference 1.02 kg) [75] . As add-on to OADs, it is, therefore, clear that in patients with a high BMI, lixisenatide has beneficial effects on body weight.
Gastrointestinal and Other Adverse Events
Across these studies, lixisenatide was generally well tolerated. As monotherapy, treatment-emergent AEs were comparable for lixisenatide and placebo (53.6% vs. 45.1%).
There were no reports of suspected pancreatitis and no instances of lipase or amylase elevation as monotherapy [77] . AEs were also similar between lixisenatide and placebo as add-on to metformin in GetGoal-F1 (68%, 71%, and 66% lixisenatide one-step titration, two-step titration and placebo, respectively) and GetGoal-M (69.4% for the lixisenatide morning injection and 60% for placebo) [72, 76] , as add-on to thiazolidinediones (72.4% and 72.7%) and as add-on to sulfonylureas with or without metformin (68.3% and 61.1%).
In the latter study, one patient in the lixisenatide group died as a result of a cardiac event after 17 days' exposure to lixisenatide [73] .
As monotherapy, 32.2% of lixisenatide-treated patients reported gastrointestinal AEs compared with 13.9% for placebo, with nausea being the most frequent (22.2% vs. 4.1%, respectively) [77] .
The majority of these events were "mild to moderate" in intensity and resolved without the need for treatment [77] . As add-on to metformin in GetGoal-F1, gastrointestinal events were reported in a higher proportion of patients − 41.6%, 47.2%, and 21.9% for lixisenatide onestep titration, two-step titration and placebo, respectively [76] , but were relatively lower in GetGoal-M as add-on to metformin, in which nausea and vomiting were reported in 22.7% and 9.4% for the lixisenatide morning injection and 7.6% and 2.9% for placebo, respectively [72] .
Comparable gastrointestinal tolerability was evident in GetGoal-S (as add-on to sulfonylureas with or without metformin) with an incidence of 40.9%
for lixisenatide and 20.0% for placebo [73] . As add-on to thiazolidinediones in GetGoal-P, rates for nausea, diarrhea, and vomiting were relatively low (23.5%, 7.1%, and 6.8% for lixisenatide vs. 10.6%, 10.6%, and 3.7% for placebo, respectively) [74] .
Gastrointestinal tolerability also appeared better for lixisenatide compared with exenatide in GetGoal-X, in which nausea, vomiting, and diarrhea were reported in 24.5%, 10.1%, and 10.4%
for lixisenatide and 35.1%, 13.3%, and 13.3% for exenatide, respectively (<0.05 for nausea) [75] .
Therefore, across these studies, the incidence of were reported in four of 239 (1.7%) lixisenatidetreated patients and two of 122 (1.6%) patients receiving placebo [77] . As add-on to metformin, cases of symptomatic hypoglycemia were three of 161 (1.9%), four of 161 (2.5%), and one of 160 (0.6%) for lixisenatide one-step titration, two-step titration and placebo, respectively in GetGoal-FI [76] , and 2.4% with a lixisenatide morning injection and 0.6% with placebo in GetGoal-M [72] . In GetGoal-S (as add-on to sulfonylureas with or without metformin), the incidence of symptomatic hypoglycemia was higher, as would be expected: 88 of 574 (15%) and 35 of 285 (12%) for lixisenatide and placebo, respectively, and there was one case of severe hypoglycemia with lixisenatide [73] . As add-on to thiazolidinediones in GetGoal-P, symptomatic hypoglycemia was reported in 11 of 320 (3.4%) with lixisenatide and two of 159 (1.2%) with placebo [74] . In GetGoal-X, six-times fewer patients experienced hypoglycemic events (eight vs. 48 patients) and three-times fewer patients experienced symptomatic hypoglycemia (eight patients with lixisenatide vs. 25 patients with exenatide); there were no cases of severe hypoglycemia in either group [75] .
These data accordingly confirm the low risk of hypoglycemia with lixisenatide, which may potentially be even lower than that associated with exenatide IR. and prevented weight gain, or induced weight loss when compared with placebo [62, 70, 71] .
Lixisenatide in Combination with
Lixisenatide as Add-On to Basal Insulin and Metformin
The GetGoal-Duo-1 study was undertaken in patients suboptimally controlled on OADs. 
Gastrointestinal and Other Adverse Events
Overall, AEs were similar for lixisenatide and placebo as add-on to basal insulin. In GetGoal-Duo-1,
AEs were reported by 80% of lixisenatide-treated patients and 68% of placebo-treated patients [71] .
In GetGoal-L, the incidence of AEs and serious
AEs was reported to be 73.5% and 3.7% for lixisenatide and 68.3% and 4.2% for placebo [70] .
No information is yet available about the incidence of cardiovascular events from these studies. In GetGoal-L-Asia, the frequency of serious treatment-emergent AEs was similar in the two groups: 6.5% in the lixisenatide group and 5.7% in the placebo group. However, two patients (1.3%)
in the lixisenatide group experienced treatmentemergent AEs of cerebrovascular infarction (nonfatal ischemic stroke) [62] . of patients receiving placebo, respectively [70] .
In GetGoal-L-Asia, rates for nausea and vomiting were 39.6% and 18.2% versus 4.5% and 1.9%
for lixisenatide and placebo, respectively [62] .
Accordingly, as add-on treatment to basal insulin, these data indicate that lixisenatide has a good overall tolerability profile, with nausea being the most common gastrointestinal AE.
Hypoglycemia
The incidence of symptomatic hypoglycemia was similar to, or only slightly increased, over placebo across these studies. As expected, in patients receiving sulfonylureas, the incidence of symptomatic hypoglycemia was higher than in those not treated with these drugs. In
GetGoal-Duo-1, a total of 22.4% of patients experienced symptomatic hypoglycemia with lixisenatide versus 13.5% for placebo [71] .
In GetGoal-L, the incidence of symptomatic hypoglycemia was similar between groups (27.7% for lixisenatide vs. 21.6% for placebo), but four cases of severe hypoglycemia occurred in the lixisenatide group [70] .
In GetGoal-L-Asia, the incidence of symptomatic hypoglycemia was more frequent with lixisenatide versus placebo (42.9% vs. 23.6%), but in patients not receiving sulfonylureas, the incidence was similar between groups (32.6% vs. 28.3%) [62] .
Effect of Lixisenatide on Body Weight
As add-on to basal insulin, lixisenatide had a beneficial effect on body weight. In GetGoalDuo-1, body weight increased by 1.2 kg in the placebo group and 0.3 kg in the lixisenatide group (LS mean difference -0.9 kg; P = 0.0012) [71] .
In GetGoal-L, body weight decreased by 1.80 kg in the lixisenatide group and 0.52 kg in the placebo group (LS mean difference -1.28 kg; P < 0.0001) [70] . In GetGoal-L-Asia, the cohort had a lower baseline BMI (Table 2) , but there was still a trend towards weight loss with lixisenatide compared with placebo (LS mean change −0.38 vs. +0.06 kg, respectively; P = not significant) [62] . 
Lixisenatide in Specific Patient Populations
